Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Col... (ment options. Chronic constipation and I...)

Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration

Date:9/17/2007

ment options. Chronic constipation and IBS-C patients are treated largely by primary care physicians, where the Forest sales force has already built excellent relationships. We are particularly excited to be working closely with Microbia, an innovative pharmaceutical company with a strong and proven management and scientific team."

Linaclotide is currently undergoing Phase 2b clinical testing in patients with IBS-C and CC. In earlier clinical studies, linaclotide demonstrated improved bowel function in patients with IBS-C and CC. These studies also showed linaclotide was well tolerated with a low incidence of adverse events. Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism distinct from previously developed products for IBS-C and CC. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure. Microbia and Forest intend to initiate Phase 3 studies in the second half of 2008.

"Joining forces with Forest is the best way to maximize linaclotide's value for patients and investors," said Peter Hecht, Microbia's Chief Executive Officer. "Forest uniquely combines world-class primary care commercial capabilities and an entrepreneurial and collaborative culture. Our companies share a common vision and commitment for getting linaclotide to IBS-C and CC sufferers."

About Irritable Bowel Syndrome (IBS)

One out of six adults in developed countries suffers from IBS, a chronic condition marked by abdominal pain and disturbed bowel function. IBS accounts for 12% of adult visits to primary care physicians and is the most common disorder diagnosed by gastroenterologists. Health care costs associated with IBS exceed $25 billion annually. IBS patients fall into three subgroups- constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and alternating (IBS-A)-and 30% to 40% of these patients suffer from IBS-C. There are currently few available ther
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Microbial Diversity in Ground and Surface Water Analyzed by Denaturing Gradient Gel Electrophoresis Using the DCode System
2. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
3. Scaling-Up from Spinners, T-Flasks & Shakers: A versatile bioreactor for mammalian and microbial cells
4. DeForest biodiesel plant begins production
5. Biodiesel plant being built in DeForest to make alternative fuel
6. Use of X-rays to advance wood-decay knowledge leads to honor for Forest Products Lab biologist
7. Biodiversity threatened as forests become islands of green, UW professor says
8. BioRobot MDx standardize your automated protocols in clinical laboratories
9. Distance-Learning Remote Laboratories using LabVIEW
10. States are the best laboratories for healthcare reform
11. Scientific Protein Laboratories Acquired by New York firm

Post Your Comments:

Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Col...(ment options. Chronic constipation and I...)